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Abstract: 
Poxvirus early genes code for viral products involved in host interaction, immune 
evasion, replication, and transcription of the viral genome. These viral early genes contain a 
unique and conserved promoter sequence that is recognized by early transcription factors (ETFs).  
The working hypothesis is pharmacologically targeting the structure of the poxvirus early 
promoters can inhibit transcription of poxvirus early genes.  Our group has identified unique 
secondary structure which deviates from a scrambled control near the Vaccinia Virus (VACV) 
E9L promoter.  Targeting these unique structures, which most likely may be G-quadruplexes, 
with structure specific ligands may distort local DNA structures at the promoter. In turn, this 
may affect the ability of viral transcription factors to recognize the target sequence. As the E9L 
gene codes for the viral DNA polymerase, inhibition of E9L transcription would prevent 
replication of the VACV DNA during infection.  To assess potential antiviral activity of G-
quadruplex ligands, the central goal of this thesis is to develop an in-vitro system to identify 
compounds that prevent binding of ETFs to target promoters. Using VACV ETFs (VETFs) as a 
model system, VETFs, A7L and D6R, were cloned into a bacterial expression vector with a His 
epitope tag for purification.  A7 and D6 have successfully been expressed and detected in 
bacterial cell lysates via immunoblotting with anti-His antibodies. Currently, protocols are being 
optimized for large-scale purification of viral proteins to use in an in vitro binding assay.   
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Introduction: 
 Poxviruses are large enveloped double stranded DNA viruses and amongst the largest of 
DNA viruses. Poxvirus genomes range from 130-375 kb in size (ViralZone). Upon entry, the 
poxvirus envelope fuses with the host membrane allowing the viral capsid to enter the 
cytoplasm. Once in the cell, poxviruses initially transcribe viral mRNAs inside the capsid to act 
as a barrier from the host cell. Unlike other DNA viruses, the entire replication cycle of a 
poxvirus occurs in the cytoplasm of the host cell. Therefore, the virus does not rely on the host’s 
transcriptional machinery in the nucleus.  Instead, a poxvirus utilizes viral transcription factors 
and a viral RNA polymerase to transcribe genes. As the poxvirus matures, it can take on two 
different mature virion forms: the intracellular mature virion or the extracellular enveloped virion 
(Condit et al. 2006). 
Vaccinia and Poxvirus Life Cycle: 
 Vaccinia Virus (VACV) is a member of the orthopoxvirus genus. VACV is the 
prototypical poxvirus that has widely been used in research labs to study poxvirus replication and 
transcription processes. VACV shares an identical life cycle to the more virulent Variola Virus 
(VARV), the causative agent of smallpox, making VACV an ideal viral model (Condit et al. 
2006). Like all poxviruses, VACV does not utilize the host cell’s transcriptional machinery 
housed within the nucleus of the cell, but instead carries its own necessary transcriptional 
machinery to regulate and express its genes. The VACV genome contains genes without introns 
that have their own promoters that code for a variety of products including transcription factors, 
RNA polymerase, DNA polymerase, structural components, and host range factors (Condit et al. 
2006). 
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 VACV regulates the transcription of its genes and life cycle temporally using three 
classes of transcription factors: Viral/Vaccinia Early Transcription Factors (VETF), 
Viral/Vaccinia Intermediate Transcription Factors (VITF), and Viral/Vaccinia Late Transcription 
Factors (VLTF) (Broyles 2003) (Figure 1). The virion core contains VETFs, the RNA 
polymerase, and a capping enzyme, which allows the VACV mRNA to be recognized for 
translation by host ribosomes (Condit et al. 2006). The VETFs bind to early gene promoters and 
recruit the RNA polymerase to express those genes.  Some early gene products include the 
poxvirus DNA polymerase, immune evasion molecules, a host range factors, and VITFs, which 
bind to intermediate promoters and express Vaccinia intermediate gene products (Broyles and Li 
1991; Broyles and Li 1993; Li and Broyles 1993; Condit et al. 2006). Some of these intermediate 
gene products are VLTFs, which induce the expression of late gene products (Broyles 2003). 
VACV late genes code for structural components of the virion (Broyles 2003). 
 The transcriptional regulation and life cycle of VACV are highly conserved in the 
orthopoxviridae genus (Broyles 2003). The transcriptional machinery is close enough to the 
point where BSC-40 cells transfected with the horsepox genome and infected with VACV can 
generate a reconstructed recombinant horsepox virus (Noyce et al. 2018). Specific regions on 
early promoters are highly conserved across orthopoxviruses: the critical region, spacer region, 
and initiation regions (Davison and Moss 1989). One important early gene promoter is the E9L 
promoter, which regulates the expression of the VACV DNA polymerase (Condit et al. 2006). 
The E9L promoter is recognized by the two VETFs: A7 and D6 (Cassetti and Moss 1996). A7 
binds the promoter and recruits D6.  D6 then recruits the RNA polymerase inducing transcription 
(Cassetti and Moss 1996, Li and Broyles 1993).  
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Figure 1. Poxvirus Replication Cycle. Poxvirus replication cycle from entry to viral exocytosis. 
This figure was generated by the author. 
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Poxvirus Diseases: 
 The most notorious of these poxviruses is the VARV, which is the causative agent of 
smallpox. VARV is a member of the orthopoxviridae genus. VARV alone has killed 
approximately 300 to 500 million people in just the 20th century alone, making it at the time one 
of the most common killers of the century (Ist and Sanit 2016). Smallpox plagued people up until 
a highly successful worldwide vaccination program led to its eradication in the late 1970’s. 
However, poxviruses still remain a topic of interest for public health. After the successful 
eradication of smallpox, the general population is now no longer vaccinated against the VARV. 
Theoretically, VARV would not pose a problem as long as all samples of VARV are 
documented, stored and/or properly disposed. However, undocumented VARV has been found in 
an FDA facility that was still infectious in 2014 (CDC (2016)). Therefore its possible  
undocumented VARV exists in other facilities around the world, and the future risk of accidental 
or intentional exposure and outbreak. Poxviruses like VARV can potentially be used as a 
bioterrorism weapon for both its transmissibility, severity, and lack of existing countermeasures. 
VACV, which is used for the VARV vaccine and part of the same orthopoxviridae family, is 
very similar genetically and antigenically to the VARV and can be engineered to be more 
virulent (Shchelkunova and Shchelkunov 2017). 
One of the most common poxviruses is the Molluscum Contagiosum Virus (MCV), which 
infects over 100 million people in the world. With the eradication of smallpox, MCV remains the 
only poxvirus that exclusively infects humans, with no animal host. MCV is mostly found in 
school children, adolescents, and immunocompromised individuals. MCV leaves distinct, benign 
skin lesions on the appendages or trunk of a host causing itchiness and mild discomfort (Nguyen 
et al. 2014).  An MCV infection usually results in mild symptoms. MCV is understudied due 
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partly to lack of a cell culture or animal model to propagate the virus. This particular limitation 
forces virologists to study MCV through cloning MCV genes in vectors and studying specific 
MCV genes and proteins. Currently there are no FDA approved treatment options, nor are there 
any widely accepted standard of care for MCV (Nguyen et al. 2014). 
Zoonotic poxviruses also remain a cause of concern to both humans and livestock. Some 
zoonotic poxviruses include VACV, cowpox virus, horsepox virus, sheeppox virus and 
cammelpox virus. Monkeypox has had consistent outbreaks in Central Africa. Like VARV, 
Monkeypox Virus is a member of the orthopoxviridae genus and shows similar signs and 
symptoms to a VARV infection (Yinka-Ogunleye et al. 2018; Haller et al. 2014). While 
Monkeypox has a lower mortality rate when compared to the smallpox, Monkeypox still poses a 
clinical threat both for the severity of its symptoms and transmissibility (Doshi et al. 2018). 
There have been outbreaks as recent as 2017 in the rural parts of Nigeria of western Africa with 
89 cases and in the Democratic Republic of Congo with over 100 cases (Yinka-Ogunleye et al. 
2018; Doshi et al. 2018; Durski et al. 2018). The most recent and only outbreak of Monkeypox in 
the United States occurred in 2003, with 47 confirmed cases in the midwest, which were 
attributed to a shipment of Monkeypox infected wild animals from West Africa to the United 
States (Durski et al. 2018). Increasing reports of the reemergence of Monkeypox virus means 
that surveillance and proper countermeasures are becoming increasingly difficult.   
Vaccinia Virus (VACV) is currently the most studied orthopoxvirus and believed to be 
originated from the cowpox vaccine. However, a recent review suggests that the VACV may 
have originated from horsepox (Esparza et al. 2017). Vaccinia is nearly identical genetically to 
VARV from its life and replication cycle, conserved genes, and transcription, which makes 
VACV used as the current smallpox live attenuated vaccine against smallpox. VACV has had 
6 
 
outbreaks in South America with many of these incidents in rural Brazil (de Oliveira et al. 2017). 
VACV naturally transmits from cattle to people (de Oliveira et al. 2017). Rodents and other 
animals can act as potential reservoirs for the VACV, which could become a major health 
concern if VACV were able to get into a densely populated urban area (de Oliveira et al. 2017). 
There are multiple strains of VACV with varying degrees of virulence, which can be a cause of 
concern, since VACV is so similar to VARV.  
Additionally, the concern for the emergence of new pathogenic poxvirus remains a public 
health concern. Recently, a new poxvirus was found in a rodent population in east central Texas 
in the United States in 2018.  The poxvirus was named Brazospox for the nearby Brazos River 
from where the poxvirus was found (Hodo et al. 2018). Brazospox was found to be closest to the 
Chorodopoxvirinae subfamily with a generated phylogram with other poxviruses (Hodo et al. 
2018). Some of its closest predicted relatives were Squirrelpox and MCV (Hodo et al. 2018). 
With the recent discovery, its pathogenicity towards humans must be assessed since Brazospox 
can potentially be a human and veterinary public health concern.   
Poxvirus Inhibitors: 
 The development and study of anti-poxviral therapeutics is necessary to control and 
prevent future and current outbreaks. The smallpox vaccine is available in the event of an 
orthopoxvirus outbreak or a bioterrorist attack.  However, the limited stock of the smallpox 
vaccine is most likely not sufficient to combat the threat of a potential outbreak, especially since 
vaccinations have ceased after its eradication in the 1980s. Cidofovir is a broad spectrum 
nucleotide analog antiviral compound that is commonly used against DNA viruses (Stittelaar et 
al. 2006). Cidofovir was successful at treating monkeypox during an outbreak (Stittelaar et al. 
2006). Cidofovir cannot be administered orally and the drug is known to be nephrotoxic, which 
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can cause major kidney damage (Foster et al. 2017). Recently, a new similar compound called 
Brincidofovir is in development to replace Cidofovir. Brincidofovir overcomes major issues of 
Cidofovir with a lipid moiety HDP conjugated to the phosphonate of Cidofovir (Foster et al 
2017). Brincidofovir was shown to be successful as an antipoxviral therapy, but poxviruses have 
been found to develop resistance similar to what has been reported with cidofovir (Foster et al. 
2017).  
One of the gold standards of orthopoxvirus inhibitors is the drug ST-246 or more 
commonly known as Tecovirimat (Mucker et al 2013). Tecovirimat targets and inhibits the 
VARV p37 protein encoded by the C17L and its homologs of the orthopoxviridae (Yang et al. 
2005). In Vaccinia, the homolog for p37 is the F13L gene which codes for the F13 protein. F13 
acts as a critical protein for the formation of the viral particle (Yang et al. 2005). The molecular 
mechanism is poorly understood for F13 and other p37 homologs (Moss 2015; Bryk et al. 2018). 
Bryk et al. recently suggested that F13 was critical to the extracellular virion formation and their 
rapid entry into cells by enhancing the sensitivity of the membrane to acid induced dissolution 
(Bryk et al. 2018). Tecovirimat has been proven to be a consistent post exposure and post 
symptomatic antipoxviral therapy against many orthopoxviruses including Monkeypox, VARV, 
VACV and Cow Pox (Berhau et al 2015; Yang et al. 2005; Mucker et al 2013). Tecovirimat 
resistance has been reported highlighting the need for continued research into novel poxvirus 
inhibitors (Pires et al. 2018; Smith et al. 2009). 
Targeting Unique DNA structures in the promoter as a novel antipoxvirus strategy: 
G-quadruplex structures consist of four guanines that fold in a planar arrangement 
through Hoogsteen hydrogen bonds (Metifiot et al. 2014). G-quadruplex structures have been 
identified in many viruses including HIV, SARS-Coronavirus, Herpes simplex virus 1, and 
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Poxviruses with functions ranging from genome stability,transcriptional regulation, and 
translational regulation (Lavezzo et al. 2018; Metifiot et al. 2014).  It would not be a surprise if 
small ligands like meso-Tetra (N-methyl-4-pyridyl) porphine tetra tosylate (TMPyP4) and N,N’-
(9-(4-(Dimethylamino)phenylamino)acridine-3,6-diyl)bis(3-(pyrrolidin-1-yl)propanamide) 
hydrochloride (BRACO-19) that bind these structures may represent a new class of anti-viral 
therapeutics.  The G quadruplex binding ligands have already been shown to inhibit HIV-1 
replication (Metifiot et al. 2014). TMPyP4 has promise as a candidate for anti-poxviral 
applications. Utilizing circular dichroism and UV-Vis drug titrations, preliminary studies 
performed by Dr. Cosimo Antonnacci and Taryn Heiser have suggested the compound has high 
specificity for the VACV DNA polymerase promoter sequence. Additionally, TMPyP4 showed 
no significant cytotoxic effect to HeLa and HEK293T cells up to 50µM (Gandbhir 2017). Since 
the G-quadruplex structure is so prevalent and based on their known function in viruses, the 
working hypothesis is that TMPyP4 binds to G quadruplex structures found at the VACV E9L 
promoter.  By binding this DNA structure, TMPyP4 may prevents A7 and D6 from binding 
DNA (Figure 2).   
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Figure 2: E9L Transcription Illustration with and without TMPyP4. This figure and all 
subsequent figures were generated by the author. 
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Direct In-Vitro Study on Viral Early Transcription Factors and Limitations on Poxvirus Studies: 
 The goal of this study is to develop a direct in-vitro screening method to identify 
compounds that inhibit viral early transcription factors (VETFs) from binding target promoters. 
Targeting VETFs is attractive target for anti-poxviral drugs. The transcription of the viral DNA 
could not only be tailored to specific VETFs, but depending on the VETF can halt or stall the 
viral replication cycle, like the E9L promoter which regulates the poxvirus DNA 
polymerase(Condit et al. 2006; Cassetti and Moss 1996). Targeting VETFs also has the added 
benefit of having a high barrier of resistance. The poxvirus would have to overcome two major 
changes. The promoter critical region that the VETFs bind to would have to be altered. These 
changes would subsequently force the VETF to undergo alterations to make it capable of binding 
to that same region and potentially become resistant. Since these regions are often highly 
conserved across the orthopoxviruses, the development of these drugs could also be a broad 
spectrum anti-poxvirus therapeutic. 
VACV provides a strong model for this study, as it is the most well studied of the 
orthopoxviruses and shares replication and transcription processes similar to other poxviruses. 
The long term goal of the project is to establish a system to perform in-vitro studies in a BSL-1 
facility A BSL-1 model would  provide  academic and nonacademic research labs a better 
opportunity to study and screen potential VETF anti-poxviral compounds, by utilizing molecular 
cloning in a bacterial model. This model would cut costs from doing live virus anti-poxviral drug 
studies in a BSL-2 or higher facility. This approach can also be applied to study binding of 
VETFs to promoters of poxviruses with BSL-3 or higher level precautions such as monkeypox 
and VARV.  Additionally, transcription factors from poxviruses that are difficult to culture, such 
as MCV, could be studied, overcoming the hurdle of not being culturable in labs (Shisler 2015).  
11 
 
The important first step of these goals is developing a reliable system to generate large quantities 
of VETF proteins using bacteria.  Purifying VETFs in bacteria has proven challenging in the past 
as both A7 and D6 are difficult to solubilize when overexpressed.  Here, the process to express, 
solubilize and purify the VACV VETFs for subsequent analysis is described.   
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Methods 
Plasmid DNA Extraction: 
DNA plasmids were extracted using the PureYield Plasmid Miniprep System protocol by 
Promega. E. coli strain DH5α transformed with either A7/pET303 (A7:pET303CT-His) or 
D6/pET303 (D6:pET303NT-His) were grown for 16-18 hours at 37oC in LB broth supplemented 
with 100 µg/mL ampicillin. Bacteria were centrifuged for 14,000 rpm for 30 seconds and then 
resuspended in 600 µL Tris EDTA Buffer. The plasmid DNA was extracted as per the 
manufacturer’s instruction and eluted with either Nuclease Free Water or Tris EDTA Buffer. The 
concentration and purity of each sample was evaluated using the NanoVue Plus 
Spectrophotometer by GE Healthcare or the BioDrop. 
Protein Expression 
A7:pET303CT-His and D6:pET303NT-His plasmid as described above and transformed 
into BL21 (DE3) E.coli. Plasmids with A260/A280 of 1.8-2 were used for the transformation. 
The transformed BL21 (DE3) were then plated on LB plates with 100 µg/mL of ampicillin. 
Isolated colonies were then taken to make glycerol stocks for preservation of culture for future 
growth and inductions. 
A starter culture of BL21 (DE3) was inoculated in 5 mL of LB broth with 100 µg/mL of 
ampicillin for 18-20 hours at 37°C and shaking at 225 rpm. This starter BL21 (DE3) culture was 
then placed into 50 mL of LB broth with 100µg/mL of ampicillin. This was also scaled up to10 
mL of starter culture into 100 mL of LB broth with 100 µg/mL of ampicillin. Once the 
OD600=0.8, D6 and A7/D6 expression was induced through addition of Isopropyl β-D-
1thiogalactopyranoside (IPTG) stimulation at 1mM for 4 hours. BL21 (DE3) cells were 
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centrifuged at 5000 xg for 10 minutes and the supernatant was discarded. The pellet was stored 
at -80°C prior to lysing. 
Immunoblotting and Commassie Staining. 
The expression of A7 and D6 was visualized through immunoblot and Coomassie 
staining. Samples were lysed and prepped by boiling for 5 minutes with 5% 2-mercaptoethanol 
in SDS sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, and 0.01% bromophenol 
blue).  Samples were resolved in a 10% SDS polyacrylamide gel electrophoresis to confirm 
expression, solubilization, and purification. These polyacrylamide gels were run at 60mA for two 
gels simultaneously or 30mA for a single gel with a buffer dam in a 1x SDS buffer containing, 
0.1% SDS, 190 mM glycine, and 25 mM Tris-Base. Polyacrylamide transferred to a 
Polyvinylidene (PVDF) membrane or Nitrocellulose membrane made by Amersham Protran for 
antibody probing with Transfer Buffer (20% Methanol, 80% water, 25.3 mM Tris Base, 19 mM 
Glycine) at 90V for 1 hour. The nitrocellulose or PVDF membranes were blocked overnight in 
5% milk (carnation non fat dry milk) 1x TBST (50mM Tris-HCl pH 7.4, 150mM NaCl, 0.1% 
Tween-20) and probed with antiHis (mouse, Thermofischer Scientific) diluted to 0.5 µg/mL in 
0.5% milk 1xTBST for 1 hour. Blots were washed in three 10 minute cycles in 0.5% milk TBST. 
The membranes were then probed with secondary antibody with Goat-α-mouse HRP by and 
diluted by 1:10,000 in 0.5% milk 1xTBST. Membranes were then washed similarly after the 
primary antibody. Bands corresponding to either His-tagged A7 or D6 were visualized with 
SuperSignal West Femto chemiluminescent reagent by Thermo Scientific for 5 minutes prior to 
using a FluorChem E imaging system.  
Alternatively, polyacrylamide gels for coomassie were stained with either Comassie blue 
(40% distilled water, 50% methanol, 10% glacial acetic acid and 0.1 g Brilliant Blue/100mL 
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solvent) and destained, or treated with SimplyBlue SafeStain by Invitrogen. The SimplyBlue 
SafeStain, the gel was rinsed for three 5 minute washes with distilled water at room temperature 
and treated with the stain for 1 hour at room temperature and shaking. After the stain was 
discarded and washed in distilled water for 1 hour, discarded and washed again in distilled water 
for 1 hour. Coomassie gels were visualized through the same FluorChem E imaging system. 
Bacterial Lysis: 
BL21 (DE3) E. coli were lysed using two different methods labeled as 6.5 pH Lysis 
Buffer and BPer method (Thermofisher Scientific). In the 6.5pH Lysis Buffer method, the 
pelleted BL21 (DE3) was resuspended into the 6.5 pH Lysis Buffer, which constituted: distilled 
water set at the pH of 6.5, 1 mg/mL of chicken egg white lysozyme, and protease cocktail 
inhibitor. The resuspended BL21 (DE3) in 6.5 pH Lysis Buffer was incubated for 30 minutes on 
ice at a ratio of 1 mL of bacterial culture into 160 µL of lysis buffer. The lysate was then 
sonicated in six 10 to 30 second bursts and intermittent 10-30 second rests, followed by 
centrifugation at 4°C at 3000 xg. Longer sonication bursts were necessary with larger volume 
lysates. The supernatant and debris were separated for analysis by immunoblot and coomassie 
staining. 
In the BPer method, the pelleted BL21 (DE3) samples were resuspended and lysed using 
the BPer buffer at a ratio of 4 mL of BPer buffer per 1 gram of bacterial pellet at room 
temperature for 15 minutes. The BPer buffer was supplemented with protease cocktail inhibitor 
by ThermoScientific, DNAse and lysosome provided by the BPer buffer lysis system 
ThermoScientific. The lysates were then sonicated similarly to the normal method at six 10 to 30 
second bursts and intermittent 10-30 second rests. The lysates were then centrifuged at 15,000 xg 
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for 5 minutes. The debris pellet and supernatant were separated for analysis by immunoblot and 
coomassie staining. 
Protein Gravity Column Purification: 
 The gravity column consisted of 1 mL of settled HisPur Ni-NTA Resin purchased from 
ThermoScientific. The resin’s storage buffer was drained by gravity flow. Then 2 mL of 
Equilibration Buffer (Table 1) was used to treat the column and allowed to flow through. The 
same Equilibration buffer was then used to treat the crude lysate in a 1:1 v/v ratio. This crude 
lysate was run through the column twice to ensure maximal protein binding to the column and 
both the crude lysate and flow through were saved as samples. The column was then washed 
with 12.5 mL of Wash (Table 1). Another wash buffer was used later with the same conditions 
supplemented with 50 mM of imidazole (Table 1). After the wash 5 mL of Elution buffer was 
then placed into the column and collected (Table 1). The Elution Buffer was also left with the 
resin overnight and collected to allow for more equilibration. A gradient elution was also done, 
in which 1.5 mL of elution buffer containing various imidazole concentrations (200 mM, 250 
mM, 300 mM, 400 mM, 450 mM and 500 mM) flowed through the column from lowest to 
highest imidazole concentration (Table 1). HisPur Ni-NTA Resin was sampled by resuspending 
the resin with Wash Buffer, pipetting the resin and transferring the resin sample into a sterile 
tube. The Resin sample resuspended in Wash Buffer was then prepped with the same method as 
the samples for the Coomassie Staining and Immunoblotting. 
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Table 1. Lysis and Purification Buffers 
 
  Buffer Name Components 
1 6.5 pH Buffer 
6.5 pH, 1mg/mL Chicken Egg Whie Lysozyme, Distilled 
Water 
2 Bper Buffer 7.5 pH, Proprietary Nonionic Detergent, 20mM Tris-HCl 
3 PBS 
20mM Sodium Phosphate, 300 mM Sodium Chloride, 
Distilled Water 
4 Equilibration Buffer 7.4 pH, 10mM Imidazole, PBS 
5 Wash Buffer 7.4 pH, 25mM or 50mM Imidazole, PBS 
6 Elution Buffer 7.4 pH, 250mM Imidazole, PBS 
7 Gradient Elution Buffer 1 7.4 pH, 200 mM Imidazole, PBS 
8 Gradient Elution Buffer 2 7.4 pH, 250 mM Imidazole, PBS 
9 Gradient Elution Buffer 3 7.4 pH, 300 mM Imidazole, PBS 
10 Gradient Elution Buffer 4 7.4 pH, 350 mM Imidazole, PBS 
11 Gradient Elution Buffer 5 7.4 pH, 400 mM Imidazole, PBS 
12 Gradient Elution Buffer 6 7.4 pH, 450 mM Imidazole, PBS 
13 Gradient Elution Buffer 7 7.4 pH, 500 mM Imidazole, PBS 
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Results:  
A7 VETF Expression and Solubilization: 
 A7 is one of two VETFs (viral early transcription factors) that bind to the E9L promoter, 
which contributes to the transcriptional regulation of VACV early genes (E9). A7 is notoriously 
difficult to purify and to our knowledge has never been attempted in a bacterial system. BL21 
(DE3) E. coli was transformed with the pET vector with A7L gene cloned into the vector 
(BL21+A7:pET303CT-His) or with the empty pET vector without A7L (BL21+pET303CT-His) 
(Gandbhir 2017). A7L is the notation of the gene for the large VETF A7 protein. The “L” 
denotes the direction of transcription of the VACV dsDNA genome. The pET303CT-His vector 
contains an in frame C-terminus his tag epitope for later detection and purification. BL21 (DE3) 
cells contain the T7 RNA polymerase to drive transcription of the insert via a T7 promoter. The 
promoter on the vector is controlled via the lac operon at the LacI binding site, which prevents 
the transcription in the absence of IPTG. BL21+A7:pET303CT-His was inoculated into Luria 
Broth (LB) with 100µg/mL of ampicillin overnight. BL21+A7:pET303CT-His starter culture 
was then transferred to fresh LB with 100µg/mL of ampicillin that was 10 times the volume of 
the original starter culture. The BL21+A7:pET303CT-His was induced 1 mM IPTG when OD600 
reached 0.8, which usually required 4 hours. After the 4 hour induction, BL21+A7:pET303CT-
His was lysed using 6.5 pH Lysis Buffer with 1mg/mL Chicken Egg White Lysozyme. This 
process was repeated with the BL21+pET303CT-His as a control. The BL21+pET303CT-His 
and BL21+A7:pET303CT-His were then compared and analyzed with a His immunoblot. A 
band corresponding to the predicted molecular weight of A7 at 83 kDa was observable in 
BL21+A7:pET303CT-His and only present in the BL21+A7:pET303CT-His with a 1mM IPTG 
treatment of 4 hours at OD600=0.8 (Figure 3). There was no observable band for 
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BL21+pET303CT-His with and without IPTG, and BL21+A7:pET303CT-His without IPTG 
(Figure 3). 
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Figure 3: His immunoblot of BL21+pET303CT-His and BL21+A7:pET303CT-His lysates in the 
presence and absence of 1mM IPTG for 4 hours.  
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A7 First Purification Attempt: 
 Once the A7 protein was visualized in the soluble portion of the lysate, these samples 
were purified via a nickel resin column. During the first A7 purification, no band corresponding 
to the predicted molecular weight (83kDa) of A7 was detected in the Elution. Instead, a band 
corresponding to the A7 was visualized in the flow through and the crude (Figure 4A, Figure 
4B). To determine if A7-His epitope tagged proteins were bound to the column, a sample of the 
resin in the column was analyzed with the corresponding A7 Purification method. The column’s 
HisPur Ni-NTA Resin was sampled and resolved by 10% SDS-PAGE for analysis via 
immunoblot and coomassie staining. An intense band corresponding to the molecular weight of 
A7 was highly detectable in the HisPur Ni-NTA Resin samples by both His immunoblot and 
Coomassie staining (Figure 4C, Figure 4D). Only the crude and flowthrough exhibited a visible 
band for the corresponding band to A7 that was detectable, but was much weaker relative to the 
HisPur Ni-NTA Resin (Figure 4C, Figure 4D). The purification attempt suggests that the elution 
was not optimized to pull off the predicted A7 from the column, however the data suggests it was 
bound to the resin. 
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A7 Purification:  
 
 
Figure 4: A7 First Purification. A) Coomassie Staining of A7 Purification. B) His Immunoblot of 
A7 Purification. C) Coomassie Staining of A7 Purification with the HisPur Ni-NTA Resin post 
Elution Buffer. D) Coomassie Staining of A7 Purification with the HisPur Ni-NTA Resin post 
Elution Buffer.  
 
C. D. 
A. B. 
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Rac Kinase Expression and Solubilization: 
Given that A7 was not successfully eluted from the column, one concern was that the His 
epitope tagged A7 was not soluble under column conditions.  Therefore, a His epitope tagged 
Rac Kinase protein, which was approximately 58 kDa, was expressed in BL21 (DE3) cells as a 
positive control. Rac Kinase is a very soluble and easily expressed in a bacterial vector system, 
which makes Rac Kinase an ideal positive expression control for the developing a bacterial 
expression system. The BL21 (DE3) cells were grown with the same bacterial induction protocol 
with 1mM of IPTG. Whole cell lysates were prepared for the SDS PAGE, by resuspending the 
bacterial pellet in an equal volume to the lysate volume of the 6.5 pH lysis buffer, which was 
then immediately prepped with SDS loading dye and 2.5% β-mercaptoethanol. 
Rac Kinase showed highly visible expression with a significant portion found in the 
lysate (Figure 5). The Debris held the highest amount of Rac Kinase, but a clear band was still 
visible in the lysate (Figure 5). The Lysate showed a weaker intensity of the Rac Kinase band in 
the absence of IPTG (Figure 5). 
 
  
 
 
 
23 
 
   Rac Kinase Expression and Solubilization:  
 
Figure 5: Rac Kinase Expression and Solubilization with and without 1mM IPTG. A) Coomassie 
Staining of Rac Kinase Expression and Solubilization. B) His Immunoblot of Rac Kinase 
Expression and Solubilization.  
 
 
B. 
A. 
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Rac Kinase Purification: 
The purification of Rac Kinase utilized the same HisPur Ni-NTA resin and followed the 
same protocol. The purification of Rac Kinase showed a visible band for the elution, however 
much of the detectable Rac Kinase was still found to be bound to the column (Figure 6). This 
suggests that the elution buffer conditions were not optimized to successfully purify our proteins 
of interest.  
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Rac Kinase Purification:  
 
 
 
Figure 6: Rac Kinase Gravity Column Purification. A) Rac Kinase Purification Coomassie 
Staining. B) His immunoblot of Rac Kinase Purification. 
 
 
 
 
 
A. B. 
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A7 Gradient Elution Purification: 
A second purification attempt on the same A7 column (Figure 4) was attempted with a 
gradient elution with varying concentrations of imidazole at 200mM, 250mM, 300mM, 400mM, 
450mM, and 500mM sequentially (Figure 7). Rac Kinase that was previously expressed and 
solubilized was used as a positive control marker (Figure 7). Under these conditions, a band 
corresponding to the expected size of A7 was detectable in all elution concentrations at 
increasing imidazole concentrations (Figure 7A, Figure 7B). Less A7-His protein was found 
bound to the resin post elution than pre-elution further indicating a successful elution (Figure 7B, 
compare lanes 3 and 4) The same column used in Figure 4 was used for this gradient elution, 
which suggests that kinetics of the elutions and column need to be optimzed. One question that 
arose at this time was whether a fraction of the protein on the column was rendered insoluble due 
to lysis conditions. Every protein is different, therefore a specific protein can have different 
interactions with the solutes and can react differently based on what buffer was used. The 
column was stored away at 4°C prior to the gradient elution, which may have also contributed to 
these results. At 4°C the lower temperature can alter the structure of the protein, while also 
affecting the kinetics of the column as well. 
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A7 Gradient Elution: Purification Attempt 2 
Figure 7: Second A7 Purification Attempt: Gradient Elution Purification was done sequentially. 
A) A7 Gradient Elution Purification Coomassie Staining. B) His immunoblot of A7 Gradient 
Elution Purification. 
A. 
B. 
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A7 Expression and Solubilization by BPer Lysis Conditions: 
The HisPur Ni-NTA resin may be optimized at 7.4 pH similar to Equilibration Buffer, 
Wash Buffer, and Elution Buffers. At the time, we postulated that an acidic pH (lower than 7.4) 
for the lysis buffer would effect the secondary structure, His tag access and solubility, which in 
turn could negatively affect the resin’s ability to bind to the His epitope tag, or release A7. 6.5 
pH lysis buffer was used because it was the optimal pH condition for the chicken egg white 
lysozyme. Therefore, BPer Buffer purchased from Thermoscientific was tested as a potentially 
more optimal lysis buffer. BPer Lysis Buffer was designed to lysis bacterial cells specifically. 
BPer Lysis Buffer’s pH ranges from 7.4 to 7.6. The BPer lysis protocol and buffer was compared 
to the 6.5 pH lysis buffer for the solubilization of A7 (Figure 8). Whole cell lysates were 
prepared similarly to conditions used on the Rac Kinase BL21 (DE3) samples (Figure 5).  
The band corresponding to A7, showed a visibly more intense band with the BPer Lysis Buffer 
conditions in comparison to the 6.5 pH Lysis Buffer (Figure 8). Since BPer was found to 
solubilize a greater proportion of the predicted A7, the BPer Buffer lysed BL21+A7:pET303CT-
His was then purified through the same HisPur Ni-NTA column and compared with the 6.5 pH 
Lysis Buffer lysed BL21+A7:pET303CT-His (Figure 8). The HisPur Ni-NTA column was eluted 
from the column with 5 mL of 400mM imidazole Elution Buffer for both the BPer Buffer and 
6.5 pH Lysis Buffer (Figure 9). 400mM imidazole Elution Buffer was used because the previous 
gradient elution showed the most intense band for both the immunoblot and coomassie stain at 
this concentration (Figure 7). The BPer Buffer Lysis method, with the purification showed both a 
more intense band for the predicted A7 (Figure 8; Figure 9). In addition, virtually all the A7 was 
removed from the resin as indicated by reduction of band intensity when comparing resin pre 
elution to resin post elution (Figure 9) 
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A7 Expression and Solubilization Optimzation with BPer: 
 
 
 
Figure 8: A7 Expression and Solubilization Optimization of A7 with the BPer buffer. A) His 
immunoblot of whole cell lysates 6.5 pH Lysis Buffer and BPer Buffer of A7. B) His 
immunoblot of lysates of 6.5 pH Lysis Buffer and BPer Buffer of A7. 
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 A7 Purification with BPer Lysis Condition:  
 
Figure 9: A7 Purification with BPer Lysis Condition. A) A7 purification lysed by 6.5 pH Lysis 
Buffer. B) A7 Purification lysed by BPer Buffer. 
A. 
B. 
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D6 Expression and Solubilization: 
 Since BPer more efficiently lysed and produced better purification results for the A7 
protein (Figure 8, Figure 9), the second VETF D6 was expressed and lysed using the BPer lysis 
buffer.  BL21 (DE3) E.coli were transformed with either BL21+D6:pET303NT-HispET303CT-
His. The BL21+D6:pET303NT-His was inoculated and induced with IPTG, following the same 
protocol used for the BL21+A7:pET303CT-His (Figure 3). The BL21+D6:pET303NT-His was 
lysed using the BPer Buffer and analyzed by an immunoblot. There was only a single visible 
band for the predicted size of D6 at 72kDa, from the BL21+D6:pET303NT-His lysate with 1mM 
of IPTG (Figure 10). There was no visible band in the absence of IPTG for 
BL21+D6:pET303NT-His lysate and BL21+pET303CT-His lysates both in the presence and 
absence of IPTG (Figure 10). 
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D6 Expression and Solubilization: 
 
Figure 10: BL21+D6:pET303NT-His and BL21+pET303CT-His Lysates Expression and 
Solubilization of D6 His Immunoblot. 
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D6 Purification: 
 Since the predicted band for D6 was observed, the next step was to purify it with the 
HisPur Ni-NTA column. D6 was purified with an elution gradient using Elution Buffer 
supplemented with increasing concentrations of imidazole (200 mM (E1), 250 mM (E2), 300 
mM (E3), 350 mM (E4), 400 mM (E5), 450 mM (E6), and 500 mM (E7)). Each buffer had a pH 
balanced to 7.4. The predicted D6 band showed clear visible bands in the crude, resin Pre 
Elution,  Elution Fraction 1(E1), and E2 (Figure 11). There was a very faint band also visible for 
E3 that matches the predicted size of D6. No band was detected when the resin was run after all 
elutions were complete indicating that the majority of the His-D6 protein was eluted from the 
column (Figure 11B).  D6 was also observed in the flow through. This may result because of the 
limited capacity of the column, where we may have just overloaded the column with D6. 
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  D6 Purification: 
 
 
Figure 11: D6 Purification. A) Coomassie staining of D6 Purification. B) His immunoblot of D6 
Purification. 
A. 
B. 
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Discussion: 
 To our knowledge, this approach represents the first attempt to utilize bacteria to express, 
solubilize and purify full-length VETFs.  A truncated version of D6 was produced in a similar 
bacterial system to generate an antibody against D6 (Broyles and Fesler 1990). Both A7 and D6 
are well known to be difficult to solubilize and purify.  Therefore, the methods generated herein 
are critical for the ultimate goal of testing bacterial purified D6 and A7 for the ability to bind 
viral early promoters such as the E9L promoter.  Once established, this system will allow the in 
vitro testing of scaffolds with an affinity for the unique sequences and structures of poxvirus 
promoters that hypothetically could inhibit binding of the VETFs. This method and these steps 
will allow a direct in vitro screen to be done safely in a BSL-1 facility, because a live virus is not 
necessary to run and reproduce these experiments. This method is cost effective method because 
BL21 (DE3) lines are much easier to maintain, select, and expression studies can be done 
overnight. Further, not all poxviruses can be cultured in mammalian tissue culture. Many 
poxviruses have a significant risk of infection and can only be studied in facilities with BSL-3 
level containment or higher (i.e. Monkeypox Virus, Variola Virus, etc..).  Once complete, our 
system will provide a cost effective and safe model to study transcription factors from these 
high-risk viruses.  
 After the successful purification of A7 and D6, these VETFs will then be directly 
assessed for their ability to bind to the E9L promoter. The E9L promoter has been cloned into a 
plasmid construct of pJet1.2 by dual restriction enzyme digest with HindIII and XbaI. The 
pJet1.2 vector also holds a single off target restriction cut site for PvuI opposite from the E9L 
promote insert.  Thus, cutting with PvuI allows the linearization of the vector.  This linearized 
construct will be tested for binding to A7 and D6 and compared to the empty pJet1.2 vector and 
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a scrambled E9L promoter sequence. To test for binding, Circular Dichroism (C.D.), Ultraviolet 
Visible Spectra (UV-Vis), and Electrophoretic Mobility Shift Assays (EMSAs) will be employed 
to determine if VETFs, A7 and D6, produced in a bacterial cell system maintain their function to 
bind viral DNA. If A7 and D6 maintain their function display visible shifts in the plasmid 
constructs withthe transcription factors, then A7 and D6 would be suggested for binding to the 
plasmid constructs. Drug binding studies can then be performed to further compare shifts in the 
spectra and assays. The plasmid constructs, A7 and D6 should have its own unique UV-Vis and 
C.D. spectras. The spectras of the A7 and D6 with the plasmid constructs should exhibit 
differences in the UV-Vis and C.D. spectra compared to the plasmid constructs alone and the A7 
and D6 alone. EMSA’s would allow us to visualize transcription factor binding, by cross linking 
the A7 and D6 onto the plasmid constructs. Running the crosslinked plasmid constructs to our 
A7 and D6 on a Western Blot and Coomassie would show larger band sizes in comparison to the 
A7 and D6 without the plasmid constructs. 
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Figure 12: E9L Promoter Constructs. A) E9L promoter construct cloned into pJet1.2 with HindII, 
xBaI, and PvuI restriction cut sites illustrated. B) E9L scrambled sequence promoter construct 
cloned into pJet1.2 with HindII, xBaI, and PvuI restriction cut sites illustrated. C) pJet1.2 vector 
with no E9L promoter insert with HindII, xBaI, and PvuI restriction cut sites illustrated. 
 
 
 
A. B. 
C. 
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It is important to note A7 and D6 produced in bacteria may not fold properly due to 
possible translational and post-translational modification that A7 and D6 may require that can 
only be done in a eukaryotic cell line. Currently, we do not anticipate post translational 
modifications to be a problem as there is no report of either A7 or D6 requiring post translational 
modification such as glycosylation. However, as an alternative approach A7 and D6 can be 
produced in an in-vitro system with eukaryotic cells. Eukaryotic cells can be transfected to 
overexpress A7 and D6 in eukaryotic cell culture line or be infected with live VACV to obtain 
A7 and D6. One potential cell line for expression and purification studies is the insect cell line 
Sf9 cells. Insect cell lines provide a happy median between mammalian cells and bacteria since 
insect cell culture is easier and cheaper to maintain than most mammalian cell culture produces 
proteins with similar post-translational modification as would be obtained from mammalian cell 
culture (McKenzie and Abbott 2018). Also insect cell lines can be transfected with plasmids to 
express signaling sequences to make A7 or D6, and then export it extracellularly. Sf9 cells have 
been previously used as well to produce viral proteins successfully like viral decoy tumor 
necrosis factor receptor and influenza nucleoproteins (Shen et al. 2014; Yoon et al. 2018). 
Through this study, A7 and D6 were expressed and purified in a bacterial system with 
BL21 (DE3) bacteria. The research described herein overcame numerous technical challenges 
and resulted in the creation of a system to overexpress and study the VETFs using bacteria.  A7 
and D6 produced and purified through this system can safely be done in a BSL-1 facility without 
the need for a live virus. This system could provide a safe and responsible screening method for 
drug design and discovery in the future. Further, the approach can be further adapted to study 
binding of poxvirus transcription factors to target promoters. When successful, this assay will 
provide a low cost and safer means in which to screen compounds for the ability to bind early 
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promoter sequences and prevent binding of VETFs, which can be later validated for antiviral 
activity in cell cultures with live virus. The assay being developed does not require the initial use 
of live virus and can be safely performed in a BSL-1 level facility. This system would potentially 
enable us to develop a new anti-poxviral therapy that targets the VACV DNA polymerase, E9L, 
early gene transcription in Poxviruses, which would halt or delay the Poxviral replication cycle. 
Because the E9L promoter is highly conserved, this drug may potentially be a broad spectrum 
anti-poxviral drug. 
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